Intellikine, Inc. and the Multiple Myeloma Research Consortium Initiate Phase I Trial of Targeted Drug INK128
LA JOLLA, Calif.--(BUSINESS WIRE)--Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a phase I trial of INK128, a novel, orally-available small molecule kinase inhibitor of the TORC1 and TORC2 complexes, in patients with multiple myeloma.